Characteristics of growth hormone therapy for pediatric patients with brain tumors in the National Cooperative Growth Study (NCGS) and from a survey of pediatric endocrinologists.
Pediatric patients with brain tumors may have significant short stature secondary to growth hormone deficiency (GHD). This occurs as a result of impaired hypothalamic function due to tumor location, radiation therapy, surgery, or chemotherapy. The use of GH replacement therapy in this patient population is variable and somewhat unpredictable. We analyzed patient data from the National Co-operative Growth Study (NCGS) database and a survey completed by 19 members of the Pediatric Endocrine Alliance for Neuro Oncology Patients (PEANOP) to identify patterns of GH use in pediatric patients following treatment for brain tumors. From the NCGS database, we present demographic, dosing, and safety data. The PEANOP survey was examined to determine the percentage of patients receiving GH and the likelihood of treating these patients with GH following tumor treatment. The time to initiating GH replacement therapy was evaluated in 14 tumor types, as well as the contributing impact of the extent of tumor resection.
Meacham
Lillian R
LR
Emory University and Children's Healthcare of Atlanta, GA 30033, USA. lmeacha@emory.edu
Sullivan
Kevin
K
D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D003625:Data Collection; D016208:Databases, Factual; D011307:Drug Prescriptions; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local
D013006:Growth Hormone